M&A Deal Summary |
|
|---|---|
| Date | 2016-11-04 |
| Target | RVR Diagnostics Sdn Bhd |
| Sector | Medical Products |
| Buyer(s) | Chembio Diagnostics |
| Deal Type | Add-on Acquisition |
| Deal Value | 2M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1985 |
| Sector | Medical Products |
| Revenue | 37M USD (2021) |
Chembio Diagnostics is a developer, manufacturer and marketer of proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets each of its DPP® HIV 1/2 Assay, HIV 1/2 STAT-PAK® Assay, and SURE CHECK® HIV 1/2 Assay, with these Chembio brand names, in the U.S. and internationally both directly and through third-party distributors. Chembio Diagnostics was incorporated in 1985 and is based in Hauppauge, New York.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Medical Products M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| Country: Malaysia M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-11-07 |
Orangelife Comercio e Industria
Rio De Janeiro, Brazil Orangelife Comercio e Industria Ltda. is a privately-held Brazilian manufacturer and distributor of point-of-care diagnostics tests for infectious diseases. Orangelife manufactures numerous ANVISA-approved point-of-care infectious disease tests, including Brazil’s first ANVISA-approved HIV self-test. Orangelife tests are manufactured in its Rio de Janeiro, Brazil facility that is ISO-certified and approved by ANVISA to produce Class II/III/IV medical devices. |
Buy | - |
